Quality control of platelet aggregation
There are many system related difficulties in the Quality Control of thrombocyte aggregation testing.
The results of platelet aggregation studies should be interpreted against the results of aggregation profiles of a normal sample tested at the same time. Here, the GpIIb/IIIa antagonist reagent can be an additional component.
The GpIIb/IIIa Antagonist Reagent is used as a positive control in platelet aggregation studies with human platelet rich plasma (PRP) or whole blood samples.
The GpIIb/IIIa Antagonist Reagent contains a synthetic inhibitor of the platelet Glyocoprotein IIb/IIIa Receptor on human platelets. This receptor is responsible for fibrinogen binding to platelets, allowing cross linking between platelets during platelet aggregation. The GpIIb/IIIa Antagonist Reagent can be added to platelet aggregation test to confirm that platelet function can be inhibited in situations where patient results are not as expected.